-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suzhou, October 11, 2021/PRNewswire/ - Development Pharmaceutical Co.
ALK-1 monoclonal antibody is a fully human monoclonal antibody that can inhibit ALK-1/TGF-β signal transduction and tumor angiogenesis.
The Phase II clinical trial (NCT03893695) of ALK-1 monoclonal antibody combined with Nivolumab for advanced HCC patients who progressed after treatment with rafenib or lenvatinib was first launched in Taiwan, China on May 7, 2019
On February 11, 2021, the Phase II clinical trial of ALK-1 monoclonal antibody combined with Nivolumab for the treatment of HCC was approved by the US FDA
Dr.
About Kaixing Pharmaceutical
Founded in 2009, Kapport Pharmaceuticals focuses on the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs, and is committed to becoming a leader in the research, development and commercialization of innovative therapies
Source: Kaifeng Pharmaceutical